Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synmosa BiopharmaROCO:4114 +0.51%84 EV-to-FCF is 98.05 as of Sep. 21, 2026, which is 236% above its 10-year median of 29.14. GuruFocus rates ROCO:4114 with a GF Score™ of 84/100 and a GF Value™ of NT$34.27 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 573 Drug Manufacturers companies, Synmosa Biopharma ranks worse than 95.46% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Synmosa Biopharma's Enterprise Value is NT$16,982 Mil.
Synmosa Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was NT$173 Mil. Therefore, Synmosa Biopharma's EV-to-FCF for today is 98.05.
The historical rank and industry rank for Synmosa Biopharma's EV-to-FCF or its related term are showing as below:
ROCO:4114'
s EV-to-FCF Range Over the Past 10 Years
Min: -254.84 Med: 29.14 Max: 328.48
Current: 278.1
During the past 13 years, the highest EV-to-FCF of Synmosa Biopharma was 328.48. The lowest was -254.84. And the median was 29.14.
ROCO:4114's EV-to-FCF is ranked worse than 95.46% of 573
companies
in the Drug Manufacturers industry
Industry Median: 19.09
vs ROCO:4114: 278.10
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Synmosa Biopharma's PE Ratio (TTM) for today is calculated as:
Synmosa Biopharma's share price for today is NT$29.80.
Synmosa Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.492.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Synmosa Biopharma EV-to-FCF Related Terms
Synmosa Biopharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Synmosa Biopharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synmosa Biopharma EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Synmosa Biopharma's EV-to-FCF falls into.
Synmosa Biopharma's current Enterprise Value is NT$16,982 Mil.
Synmosa Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$173 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synmosa Biopharma (ROCO:4114) has a EV-to-FCF of 98.05 as of Sep. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Synmosa Biopharma and its competitors. This is 236% above median its historical median of 29.14. According to the industry distribution chart, Synmosa Biopharma ranks #547 out of 573 companies in the Drug Manufacturers industry, placing it in the top 95.5%.
Is Synmosa Biopharma's EV-to-FCF too high?
Synmosa Biopharma's current EV-to-FCF of 98.05 is 236% above median its 10-year median of 29.14. The Drug Manufacturers industry median EV-to-FCF is 19.09. Synmosa Biopharma's value of 98.05 is 413.6% above this industry median. Based on the distribution chart, Synmosa Biopharma ranks #547 out of 573 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Synmosa Biopharma has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Synmosa Biopharma ranks #547 out of 573 companies for EV-to-FCF. This places Synmosa Biopharma in the lower half of its industry. The industry median EV-to-FCF is 19.09. Synmosa Biopharma's value of 98.05 is 413.6% above this benchmark. While the company's 10-year median is 29.14 vs. the industry median of 19.09, Synmosa Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.09, based on 573 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synmosa Biopharma's current EV-to-FCF of 98.05 is 413.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Synmosa Biopharma and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synmosa Biopharma's current EV-to-FCF is 98.05, which is 236% above median its own 10-year median of 29.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$34.27, compared to a current price of NT$29.80 — trading 13% below its estimated fair value. The current EV-to-FCF is 98.05, which is 236% above median its 10-year median of 29.14 and 413.6% above the Drug Manufacturers industry median of 19.09. Synmosa Biopharma's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current EV-to-FCF is 98.05 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?
Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued.
The current stock price of NT$29.80 is trading 13% below its estimated GF Value™ of NT$34.27.
GuruFocus considers Synmosa Biopharma to be Modestly Undervalued.
Key valuation signals for ROCO:4114:
EV-to-FCF: 98.05 (236% above median its 10-year median of 29.14)
GF Value™: NT$34.27 vs. price of NT$29.80 (13% below fair value)
Industry Position: 413.6% above the Drug Manufacturers median (#547 of 573)
No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
84GF Score
Get the complete analysis for ROCO:4114
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4114 has been successfully added to your 
